Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MT-8421 |
| Trade Name | |
| Synonyms | MT8421|MT 8421 |
| Drug Descriptions |
MT-8421 is an engineered toxin body that targets regulatory T-cells expressing high levels of CTLA-4, potentially resulting in decreases in regulatory T-cells in the tumor microenvironment and increased proliferation of CD8- and CD4-positive T-cells (Journal for ImmunoTherapy of Cancer (2022), 83 (Supplement 2): 817). |
| DrugClasses | CTLA4 Antibody 33 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| MT-8421 | MT-8421 | 0 | 1 |
| MT-8421 + Nivolumab | MT-8421 Nivolumab | 0 | 1 |